Drug Healthcare and Patient Safety is a premier Open Access journal, published by DOVE MEDICAL PRESS LTD since 2009, dedicated to advancing the understanding and practices surrounding medication safety and healthcare delivery. With its ISSN 1179-1365 and E-ISSN matching, this New Zealand-based journal not only fosters global discourse but also prioritizes the dissemination of research that intersects both health policy and pharmacology. Categorized as Q2 in Health Policy and Q3 in Pharmacology for the year 2023, it occupies a notable position within the academic community, as reflected by its Scopus rankings, which place it in the 66th and 45th percentiles of its respective categories. Drug Healthcare and Patient Safety aims to provide a platform for researchers, practitioners, and students to share innovative findings, promote safe medication practices, and explore the implications of health policy on patient outcomes. As an Open Access journal, it ensures that vital research is accessible to a wider audience, making significant contributions to the ongoing dialogue in the fields of healthcare and pharmacovigilance.

American Journal of Medical Quality is a pivotal publication in the field of healthcare quality and medical policy, published by Lippincott Williams & Wilkins. Since its inception in 1992, the journal has become a critical resource for researchers, practitioners, and students dedicated to improving patient care and health systems through evidence-based practices. With a current impact factor that reflects its significance in the arena of medicine and health policy, the journal falls within the Q3 category in both Health Policy and Medicine (Miscellaneous) as of 2023, ranking 253rd out of 636 in general medicine according to Scopus metrics. This underscores its relevance and prominence among peers. The journal's scope encompasses a diverse range of topics related to quality improvement initiatives, healthcare delivery systems, and policy analysis, making it an essential read for anyone invested in advancing medical quality standards and practices. While it is not an open-access journal, the content is meticulously curated to enrich the academic discourse and inform best practices in medical quality. With an ongoing commitment to addressing contemporary challenges in healthcare, American Journal of Medical Quality serves as an influential platform for advancing the knowledge and implementation of quality initiatives in medical settings.

The British Journal of Anaesthesia is a leading peer-reviewed journal published by Elsevier Science Ltd, dedicated to advancing the field of anesthesiology and pain medicine. Since its inception in 1923, this prestigious journal has served as a vital resource for clinicians, researchers, and students, providing high-quality research articles, reviews, and clinical guidelines. With an impressive impact factor and a Scopus rank of #2 out of 136 in its category, it stands out as a Q1 journal, reflecting its significance and influence in the medical community. The journal aims to disseminate innovative research findings, enhance clinical practice, and contribute to the education of healthcare professionals globally. Although it does not offer open access, its rich archive and ongoing publication in the dynamic field of anesthesiology make it an essential reference for those seeking to stay at the forefront of this critical discipline. For more information, visit the journal’s dedicated webpage.

Therapeutics and Clinical Risk Management is a pioneering journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the fields of medication safety, pharmacology, and clinical risk management through rigorous research and comprehensive reviews. With an impact factor that demonstrates its significance within various disciplines, this Open Access journal has been instrumental since its inception in 2006, promoting the dissemination of knowledge to a global audience without barriers. With its reach spanning categories such as Pharmacology, Medicine, and Chemical Health and Safety, it champions innovative practices and risk assessment methodologies. The journal is recognized in the Q2 quartile for multiple related categories and excels in rank within its field, highlighting its influential contributions to safety and therapeutic practices. By prioritizing the sharing of impactful research, Therapeutics and Clinical Risk Management serves as an indispensable resource for researchers, professionals, and students aiming to enhance clinical outcomes and mitigate risks in therapeutic paradigms.

Safety is a prestigious Open Access journal published by MDPI, based in Switzerland, dedicated to advancing research in the fields of public health, environmental safety, and occupational health. Since its inception in 2015, the journal has become a vital resource for researchers, practitioners, and policymakers, striving to foster innovative solutions to safety challenges in various sectors. With its rigorous peer-review process and a 2023 ranking in the Q2 category for Safety Research, as well as a notable presence in public health and environmental disciplines, Safety is well-respected in academic circles, holding a Scopus rank of 37/109 in Safety Research and 87/207 in Safety, Risk, Reliability, and Quality. The journal aims to disseminate high-quality research that not only reflects the latest advancements but also aids in developing practical strategies for risk management and safety improvement. Supported by an open-access model, Safety ensures that cutting-edge research is readily available to a global audience, fostering collaboration and knowledge sharing for a safer environment.

INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE, published by Oxford University Press, stands as a pivotal resource in the domains of Health Policy, Medicine, and Public Health. With an ISSN of 1353-4505 and an E-ISSN of 1464-3677, this journal has been a cornerstone for quality assessment in healthcare since its inception in 1989, evolving through to 2024. Holding a respected position in the academic community, it is classified in the Q2 category across multiple fields including Health Policy and Environmental Health, reflecting its significant impact as evidenced by its Scopus rankings (Rank #74/310 in Health Policy, Percentile 76th). Though it operates under a subscription model, the journal aims to disseminate pioneering research aimed at improving healthcare quality globally, providing insights that are invaluable for researchers, practitioners, and policymakers alike. With a commitment to enhancing public health landscapes, the journal continues to influence practices and outcomes in a rapidly changing health environment.

Expert Opinion on Drug Safety is a prestigious academic journal dedicated to advancing knowledge in the fields of drug safety and pharmacology. Published by Taylor & Francis Ltd, this journal serves as an essential resource for researchers and professionals seeking to explore the complexities of drug interactions, adverse effects, and risk management. With an impressive impact factor and recognized as a Q1 journal in both the Medicine (Miscellaneous) and Pharmacology (Medical) categories, it ranks favorably at #78 out of 272 in Scopus, placing it in the 71st percentile among its peers. Operating under a rigorous peer-review process, the journal publishes original research, expert reviews, and opinion pieces that contribute to a deeper understanding of drug safety practices. While not an open access journal, it remains a vital platform for disseminating pivotal findings and fostering scholarly dialogue, ensuring that critical insights reach a global audience. With continuous publication from 2002 to 2024, Expert Opinion on Drug Safety is a key reference for anyone involved in pharmaceutical research, healthcare practice, or drug regulation.

Current Drug Safety is a distinguished peer-reviewed journal published by Bentham Science Publishers, focusing on the critical intersection of pharmacology and toxicology. With an ISSN of 1574-8863 and an E-ISSN of 2212-3911, this journal serves as a platform for the latest research and advances in drug safety, highlighting the importance of pharmacological assessments and toxicity evaluations in therapeutic development and public health. Reaching a broad international audience from its base in the United Arab Emirates, Current Drug Safety offers an invaluable resource for researchers, professionals, and students interested in the dynamic fields of drug research and safety management. Despite a current Q3 categorization in multiple pharmacology and toxicology quartiles for 2023, the journal continues to strive for excellence in the scholarly community, reflecting its commitment to disseminating high-quality research. While not operating under an open access model, articles can be accessed through institutional subscriptions and other platforms, ensuring valuable insights into drug safety are available to those who need it most.

The Journal of Patient Safety, published by Lippincott Williams & Wilkins, is a premier scholarly journal dedicated to advancing the field of patient safety through empirical research, innovative practices, and critical insights. Established in 2006, this journal has rapidly gained recognition, currently holding a prestigious Q1 ranking in Leadership and Management and a Q2 ranking in Public Health, Environmental and Occupational Health for 2023, reflecting its significant impact within these disciplines. With an impressive rank of #7 in Nursing Leadership and Management and #211 in Medicine Public Health as recorded in Scopus, this journal serves as an essential resource for researchers, healthcare professionals, and students committed to improving patient safety and outcomes. The journal does not operate as an open access publication; however, its comprehensive scope and high-quality articles underscore its dedication to disseminating crucial knowledge in a field that is ever-evolving. Joining the readership of the Journal of Patient Safety means becoming part of a vital conversation aimed at redefining standards of care and enhancing safety protocols across various healthcare settings.

DRUGS & THERAPY PERSPECTIVES is an esteemed journal published by SpringerNature, dedicated to advancing knowledge in the field of pharmacology and therapeutic studies. With an ISSN of 1172-0360 and an E-ISSN of 1179-1977, this journal has been providing valuable insights since its inception in 1993 and continues to publish until 2024. Ranked in the Q3 category for Pharmacology (medical) and positioned within the 25th percentile according to Scopus rankings, it serves as a vital resource for researchers, practitioners, and students alike. Although it is not an open-access journal, it offers a comprehensive platform for innovative research, clinical practices, and evolving therapeutic strategies, reflecting the critical developments in drug therapy landscape. With its strategic emphasis on bridging academic studies and clinical applications, DRUGS & THERAPY PERSPECTIVES remains essential for those committed to enhancing drug efficacy and patient outcomes in the ever-evolving medical field.